Featured: Turning the Tide Against Superbugs
MBL inhibitors could be India’s best shot at defeating deadly superbugs. In this expert article, Mr. Saransh Chaudhary, President – Global Critical Care at Venus Remedies and CEO of VMRC, shares why innovation and collaboration are key.
Metallo-β-lactamases (MBLs) are among the most dangerous enzymes produced by drug-resistant bacteria. They render last-line antibiotics like carbapenems ineffective—posing a serious threat to critical care treatment in India and across the globe.
With the rising rates of antimicrobial resistance (AMR), particularly in Gram-negative infections, the development of MBL inhibitors has become a pressing national and global priority.
“Turning the Tide Against Superbugs: Why MBL Inhibitors Are Crucial for India’s Fight Against AMR.”
This featured article by Mr. Saransh Chaudhary, President – Global Critical Care at Venus Remedies and CEO of Venus Medicine Research Centre (VMRC), in BW HealthcareWorld highlights the need for innovative drug discovery approaches to combat AMR.
Why MBL Inhibitors Matter in India’s AMR Response
We face a growing threat of metallo‑β‑lactamase (MBL)–producing bacteria, a key driver of antimicrobial resistance in India. Experts say that conventional β-lactamase inhibitors are inadequate against MBLs. This highlights an urgent need for next‑generation compounds to restore antibiotic efficacy.
However, AMR continues to escalate, limiting our ability to treat severe infections and increasing mortality. Without targeted interventions like MBL inhibitors, India’s healthcare system and patients face increased risks.
The Need for Innovative Solutions
MBL inhibitor research needs active participation and investment to address the AMR threat in India. The expert perspective of Mr Saransh is rooted in his expertise and experience in critical care challenges. He discusses how coordinated efforts between government, industry, and research institutions can accelerate progress.
Our Commitment: Innovation at the Frontlines
At Venus Remedies, we prioritize high‑value injectables. Fighting AMR through novel antibiotic adjuvants such as MBL inhibitors is a part of our mission to increase the global healthcare standards. This also translates to investment in R&D that responds to eliminating public health threats - not only within oncology or critical care but across broader therapeutic areas.
Our collective focus involves keeping up with the regulatory frameworks, pursuing robust clinical development, and collaborating with stakeholders across India. He also highlights the need for structured support—policy alignment, funding, and scientific exchange—to ensure innovation translates into impact.
Collaboration is Essential
AMR is not an individual problem, but one that requires a coordinated, multi‑sector approach.
Government leadership, academic expertise, and private‑sector agility must work together to mitigate this threat. Therefore, to build a synergy and “turning the tide” requires both novel science and ecosystems that enable innovation at scale.
This message resonates deeply within our cross-functional teams who bring this vision to life in day-to-day operations.
Looking Ahead: Directions for Impact
The emergence of MBL inhibitors is more than a technological advance; it shows a shift in how India confronts AMR scientifically and systematically. As demand for innovative therapies grows, Venus Remedies is exploring partnerships and research initiatives to contribute at scale.
Our ambition extends beyond product development. We seek to support policy frameworks, AMR surveillance, and public‑private collaboration so that scientific breakthroughs become accessible treatment options. It speaks to our collective journey in critical care innovation and global health. As motivation to deepen our work in AMR, antimicrobial innovation, and healthcare access across our regions.
